Current update on the molecular genetics and management of hereditary ovarian cancers: a primer for radiologists.
BRCA mutation
Gorlin syndrome
Hereditary ovarian cancer
Lynch syndrome
Peutz-Jeghers syndrome
Journal
Abdominal radiology (New York)
ISSN: 2366-0058
Titre abrégé: Abdom Radiol (NY)
Pays: United States
ID NLM: 101674571
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
03
08
2020
accepted:
11
12
2020
revised:
09
12
2020
pubmed:
14
4
2021
medline:
22
6
2021
entrez:
13
4
2021
Statut:
ppublish
Résumé
More than one-fifth of ovarian cancers are hereditary, with most of them caused by BRCA genes. Malignant ovarian neoplasms are primarily epithelial tumors, a heterogeneous group of tumors with variable genetic backgrounds that translate into different biologic behaviors and morphologic features. Radiologists play an increasingly important role in the diagnosis and management of oncology patients. Familiarity with hereditary ovarian cancers will have a positive impact on patient management and radiologists' involvement in the multidisciplinary approach needed for this delicate patient population. In this paper, we review the basic histologic and genetic backgrounds of ovarian tumors with an emphasis on hereditary ovarian cancers, as well as the effects that these factors have on patient workup, primarily with regard to imaging studies.
Identifiants
pubmed: 33847772
doi: 10.1007/s00261-020-02911-x
pii: 10.1007/s00261-020-02911-x
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2281-2292Références
Doubeni CA, Doubeni AR, Myers AE (2016) Diagnosis and Management of Ovarian Cancer. Am Fam Physician 93 (11):937-944
pubmed: 27281838
SEER Cancer Statistics Review, 1975–2017, based on November 2019 SEER data submission. National Cancer Institute. https://seer.cancer.gov/csr/1975_2017/ . Accessed 6/27/2020
Toss A, Tomasello C, Razzaboni E, Contu G, Grandi G, Cagnacci A, Schilder RJ, Cortesi L (2015) Hereditary ovarian cancer: not only BRCA 1 and 2 genes. Biomed Res Int 2015:341723. https://doi.org/10.1155/2015/341723
doi: 10.1155/2015/341723
pubmed: 26075229
pmcid: 4449870
Kasprzak L, Foulkes WD, Shelling AN (1999) Forth nightly review: hereditary ovarian carcinoma. BMJ 318 (7186):786-789. https://doi.org/10.1136/bmj.318.7186.786
doi: 10.1136/bmj.318.7186.786
pubmed: 10082707
pmcid: 1115218
Desai A, Xu J, Aysola K, Qin Y, Okoli C, Hariprasad R, Chinemerem U, Gates C, Reddy A, Danner O, Franklin G, Ngozi A, Cantuaria G, Singh K, Grizzle W, Landen C, Partridge EE, Rice VM, Reddy ES, Rao VN (2014) Epithelial ovarian cancer: An overview. World J Transl Med 3 (1):1-8. https://doi.org/10.5528/wjtm.v3.i1.1
doi: 10.5528/wjtm.v3.i1.1
pubmed: 25525571
pmcid: 4267287
Low JJ, Ilancheran A, Ng JS (2012) Malignant ovarian germ-cell tumours. Best Pract Res Clin Obstet Gynaecol 26 (3):347-355. https://doi.org/10.1016/j.bpobgyn.2012.01.002
doi: 10.1016/j.bpobgyn.2012.01.002
pubmed: 22301054
Jung SE, Rha SE, Lee JM, Park SY, Oh SN, Cho KS, Lee EJ, Byun JY, Hahn ST (2005) CT and MRI findings of sex cord-stromal tumor of the ovary. AJR Am J Roentgenol 185 (1):207-215. https://doi.org/10.2214/ajr.185.1.01850207
doi: 10.2214/ajr.185.1.01850207
pubmed: 15972425
Kurman RJ (2013) Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. Ann Oncol 24 Suppl 10:x16-21. https://doi.org/10.1093/annonc/mdt463
doi: 10.1093/annonc/mdt463
pubmed: 24265397
Kurman RJ, Shih Ie M (2010) The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 34 (3):433-443. https://doi.org/10.1097/PAS.0b013e3181cf3d79
doi: 10.1097/PAS.0b013e3181cf3d79
pubmed: 20154587
pmcid: 2841791
Weinberger V, Minar L, Felsinger M, Ovesna P, Bednarikova M, Cihalova M, Jandakova E, Hausnerova J, Chaloupkova B, Zikan M (2018) Brenner tumor of the ovary - ultrasound features and clinical management of a rare ovarian tumor mimicking ovarian cancer. Ginekol Pol 89 (7):357-363. https://doi.org/10.5603/GP.a2018.0061
doi: 10.5603/GP.a2018.0061
pubmed: 30091444
Koshiyama M, Matsumura N, Konishi I (2014) Recent concepts of ovarian carcinogenesis: type I and type II. Biomed Res Int 2014:934261. https://doi.org/10.1155/2014/934261
doi: 10.1155/2014/934261
pubmed: 24868556
pmcid: 4017729
Dubeau L (2008) The cell of origin of ovarian epithelial tumours. Lancet Oncol 9 (12):1191-1197. https://doi.org/10.1016/S1470-2045(08)70308-5
doi: 10.1016/S1470-2045(08)70308-5
pubmed: 19038766
pmcid: 4176875
Jung SE, Lee JM, Rha SE, Byun JY, Jung JI, Hahn ST (2002) CT and MR imaging of ovarian tumors with emphasis on differential diagnosis. Radiographics 22 (6):1305-1325. https://doi.org/10.1148/rg.226025033
doi: 10.1148/rg.226025033
pubmed: 12432104
Boussios S, Mikropoulos C, Samartzis E, Karihtala P, Moschetta M, Sheriff M, Karathanasi A, Sadauskaite A, Rassy E, Pavlidis N (2020) Wise Management of Ovarian Cancer: On the Cutting Edge. J Pers Med 10 (2). https://doi.org/10.3390/jpm10020041
Hollis RL, Gourley C (2016) Genetic and molecular changes in ovarian cancer. Cancer Biol Med 13 (2):236-247. https://doi.org/10.20892/j.issn.2095-3941.2016.0024
doi: 10.20892/j.issn.2095-3941.2016.0024
pubmed: 27458531
pmcid: 4944549
Lim D, Oliva E (2013) Precursors and pathogenesis of ovarian carcinoma. Pathology 45 (3):229-242. https://doi.org/10.1097/PAT.0b013e32835f2264
doi: 10.1097/PAT.0b013e32835f2264
pubmed: 23478230
Manchana T, Phoolcharoen N, Tantbirojn P (2019) BRCA mutation in high grade epithelial ovarian cancers. Gynecol Oncol Rep 29:102-105. https://doi.org/10.1016/j.gore.2019.07.007
doi: 10.1016/j.gore.2019.07.007
pubmed: 31467961
pmcid: 6710551
George SH, Shaw P (2014) BRCA and Early Events in the Development of Serous Ovarian Cancer. Front Oncol 4:5. https://doi.org/10.3389/fonc.2014.00005
doi: 10.3389/fonc.2014.00005
pubmed: 24478985
pmcid: 3901362
Kobayashi H, Ohno S, Sasaki Y, Matsuura M (2013) Hereditary breast and ovarian cancer susceptibility genes (review). Oncol Rep 30 (3):1019-1029. https://doi.org/10.3892/or.2013.2541
doi: 10.3892/or.2013.2541
pubmed: 23779253
Williams SA, Wilson JB, Clark AP, Mitson-Salazar A, Tomashevski A, Ananth S, Glazer PM, Semmes OJ, Bale AE, Jones NJ, Kupfer GM (2011) Functional and physical interaction between the mismatch repair and FA-BRCA pathways. Hum Mol Genet 20 (22):4395-4410. https://doi.org/10.1093/hmg/ddr366
doi: 10.1093/hmg/ddr366
pubmed: 21865299
pmcid: 3196888
Neff RT, Senter L, Salani R (2017) BRCA mutation in ovarian cancer: testing, implications and treatment considerations. Ther Adv Med Oncol 9 (8):519-531. https://doi.org/10.1177/1758834017714993
doi: 10.1177/1758834017714993
pubmed: 28794804
pmcid: 5524247
Savage KI, Matchett KB, Barros EM, Cooper KM, Irwin GW, Gorski JJ, Orr KS, Vohhodina J, Kavanagh JN, Madden AF, Powell A, Manti L, McDade SS, Park BH, Prise KM, McIntosh SA, Salto-Tellez M, Richard DJ, Elliott CT, Harkin DP (2014) BRCA1 deficiency exacerbates estrogen-induced DNA damage and genomic instability. Cancer Res 74 (10):2773-2784. https://doi.org/10.1158/0008-5472.CAN-13-2611
doi: 10.1158/0008-5472.CAN-13-2611
pubmed: 24638981
pmcid: 4024319
Hamada J, Nakata D, Nakae D, Kobayashi Y, Akai H, Konishi Y, Okada F, Shibata T, Hosokawa M, Moriuchi T (2001) Increased oxidative DNA damage in mammary tumor cells by continuous epidermal growth factor stimulation. J Natl Cancer Inst 93 (3):214-219. https://doi.org/10.1093/jnci/93.3.214
doi: 10.1093/jnci/93.3.214
pubmed: 11158190
Moorman PG, Havrilesky LJ, Gierisch JM, Coeytaux RR, Lowery WJ, Peragallo Urrutia R, Dinan M, McBroom AJ, Hasselblad V, Sanders GD, Myers ER (2013) Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol 31 (33):4188-4198. https://doi.org/10.1200/JCO.2013.48.9021
doi: 10.1200/JCO.2013.48.9021
pubmed: 24145348
Faraoni I, Graziani G (2018) Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors. Cancers (Basel) 10 (12). https://doi.org/10.3390/cancers10120487
Jang E, Chung DC (2010) Hereditary colon cancer: lynch syndrome. Gut Liver 4 (2):151-160. https://doi.org/10.5009/gnl.2010.4.2.151
doi: 10.5009/gnl.2010.4.2.151
pubmed: 20559516
pmcid: 2886941
Nakamura K, Banno K, Yanokura M, Iida M, Adachi M, Masuda K, Ueki A, Kobayashi Y, Nomura H, Hirasawa A, Tominaga E, Aoki D (2014) Features of ovarian cancer in Lynch syndrome (Review). Mol Clin Oncol 2 (6):909-916. https://doi.org/10.3892/mco.2014.397
doi: 10.3892/mco.2014.397
pubmed: 25279173
pmcid: 4179837
Lynch HT, Casey MJ, Snyder CL, Bewtra C, Lynch JF, Butts M, Godwin AK (2009) Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Mol Oncol 3 (2):97-137. https://doi.org/10.1016/j.molonc.2009.02.004
doi: 10.1016/j.molonc.2009.02.004
pubmed: 19383374
pmcid: 2778287
Helder-Woolderink JM, Blok EA, Vasen HF, Hollema H, Mourits MJ, De Bock GH (2016) Ovarian cancer in Lynch syndrome; a systematic review. Eur J Cancer 55:65-73. https://doi.org/10.1016/j.ejca.2015.12.005
doi: 10.1016/j.ejca.2015.12.005
pubmed: 26773421
Ryan NAJ, Evans DG, Green K, Crosbie EJ (2017) Pathological features and clinical behavior of Lynch syndrome-associated ovarian cancer. Gynecol Oncol 144 (3):491-495. https://doi.org/10.1016/j.ygyno.2017.01.005
doi: 10.1016/j.ygyno.2017.01.005
pubmed: 28065618
pmcid: 5345899
Helleman J, van Staveren IL, Dinjens WN, van Kuijk PF, Ritstier K, Ewing PC, van der Burg ME, Stoter G, Berns EM (2006) Mismatch repair and treatment resistance in ovarian cancer. BMC Cancer 6:201. https://doi.org/10.1186/1471-2407-6-201
doi: 10.1186/1471-2407-6-201
pubmed: 16879751
pmcid: 1557864
Tuna M, Ju Z, Yoshihara K, Amos CI, Tanyi JL, Mills GB (2020) Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers. Br J Cancer 122 (3):405-412. https://doi.org/10.1038/s41416-019-0654-8
doi: 10.1038/s41416-019-0654-8
pubmed: 31780779
Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, Roeb W, Agnew KJ, Stray SM, Wickramanayake A, Norquist B, Pennington KP, Garcia RL, King MC, Swisher EM (2011) Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A 108 (44):18032-18037. https://doi.org/10.1073/pnas.1115052108
doi: 10.1073/pnas.1115052108
pubmed: 22006311
pmcid: 3207658
Schultz KA, Harris A, Messinger Y, Sencer S, Baldinger S, Dehner LP, Hill DA (2016) Ovarian tumors related to intronic mutations in DICER1: a report from the international ovarian and testicular stromal tumor registry. Fam Cancer 15 (1):105-110. https://doi.org/10.1007/s10689-015-9831-y
doi: 10.1007/s10689-015-9831-y
pubmed: 26289771
pmcid: 4699873
Pirschner F, Bastos PM, Contarato GL, Bimbato AC, Filho AC (2012) Gorlin syndrome and bilateral ovarian fibroma. Int J Surg Case Rep 3 (9):477-480. https://doi.org/10.1016/j.ijscr.2012.05.015
doi: 10.1016/j.ijscr.2012.05.015
pubmed: 22771908
pmcid: 3397296
Kimonis VE, Goldstein AM, Pastakia B, Yang ML, Kase R, DiGiovanna JJ, Bale AE, Bale SJ (1997) Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet 69 (3):299-308
doi: 10.1002/(SICI)1096-8628(19970331)69:3<299::AID-AJMG16>3.0.CO;2-M
Banno K, Kisu I, Yanokura M, Masuda K, Ueki A, Kobayashi Y, Hirasawa A, Aoki D (2013) Hereditary gynecological tumors associated with Peutz-Jeghers syndrome (Review). Oncol Lett 6 (5):1184-1188. https://doi.org/10.3892/ol.2013.1527
doi: 10.3892/ol.2013.1527
pubmed: 24179492
pmcid: 3813608
Matsubayashi H, Higashigawa S, Kiyozumi Y, Horiuchi Y, Hirashima Y, Kado N, Abe M, Ohishi T, Ohnami S, Urakami K, Yamaguchi K (2019) Metachronous ovarian endometrioid carcinomas in a patient with a PTEN variant: case report of incidentally detected Cowden syndrome. BMC Cancer 19 (1):1014. https://doi.org/10.1186/s12885-019-6272-2
doi: 10.1186/s12885-019-6272-2
pubmed: 31664961
pmcid: 6819610
Yauy K, Imbert-Bouteille M, Bubien V, Lindet-Bourgeois C, Rathat G, Perrochia H, MacGrogan G, Longy M, Bessis D, Tinat J, Baert-Desurmont S, Blanluet M, Perre PV, Baudry K, Pujol P, Corsini C (2019) Ovarian Clear Cell Carcinoma in Cowden Syndrome. J Natl Compr Canc Netw 17 (1):7-11. https://doi.org/10.6004/jnccn.2018.7065
doi: 10.6004/jnccn.2018.7065
pubmed: 30659124
Gammon A, Jasperson K, Champine M (2016) Genetic basis of Cowden syndrome and its implications for clinical practice and risk management. Appl Clin Genet 9:83-92. https://doi.org/10.2147/TACG.S41947
doi: 10.2147/TACG.S41947
pubmed: 27471403
pmcid: 4948690
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 1.2020 www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf .
Hampel H, Bennett RL, Buchanan A, Pearlman R, Wiesner GL, Guideline Development Group ACoMG, Genomics Professional P, Guidelines C, National Society of Genetic Counselors Practice Guidelines C (2015) A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genet Med 17 (1):70-87. https://doi.org/10.1038/gim.2014.147
doi: 10.1038/gim.2014.147
This P, de la Rochefordiere A, Savignoni A, Falcou MC, Tardivon A, Thibault F, Alran S, Fourchotte V, Fitoussi A, Couturaud B, Dolbeault S, Salmon RJ, Sigal-Zafrani B, Asselain B, Stoppa-Lyonnet D, Institut Curie B, Ovarian Cancer Risk Study G (2012) Breast and ovarian cancer risk management in a French cohort of 158 women carrying a BRCA1 or BRCA2 germline mutation: patient choices and outcome. Fam Cancer 11 (3):473-482. https://doi.org/10.1007/s10689-012-9539-1
doi: 10.1007/s10689-012-9539-1
Marchetti C, De Felice F, Palaia I, Perniola G, Musella A, Musio D, Muzii L, Tombolini V, Panici PB (2014) Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers. BMC Womens Health 14:150. https://doi.org/10.1186/s12905-014-0150-5
doi: 10.1186/s12905-014-0150-5
pubmed: 25494812
pmcid: 4271468
Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, Offit K (2002) Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res 8 (12):3776-3781
pubmed: 12473589
Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, Reding DJ, Greenlee RT, Yokochi LA, Kessel B, Crawford ED, Church TR, Andriole GL, Weissfeld JL, Fouad MN, Chia D, O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hartge P, Pinsky PF, Zhu CS, Izmirlian G, Kramer BS, Miller AB, Xu JL, Prorok PC, Gohagan JK, Berg CD, Team PP (2011) Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 305 (22):2295-2303. https://doi.org/10.1001/jama.2011.766
doi: 10.1001/jama.2011.766
Kamal R, Hamed S, Mansour S, Mounir Y, Abdel Sallam S (2018) Ovarian cancer screening-ultrasound; impact on ovarian cancer mortality. Br J Radiol 91 (1090):20170571. https://doi.org/10.1259/bjr.20170571
doi: 10.1259/bjr.20170571
pubmed: 30102555
pmcid: 6350495
Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, Amso NN, Apostolidou S, Benjamin E, Cruickshank D, Crump DN, Davies SK, Dawnay A, Dobbs S, Fletcher G, Ford J, Godfrey K, Gunu R, Habib M, Hallett R, Herod J, Jenkins H, Karpinskyj C, Leeson S, Lewis SJ, Liston WR, Lopes A, Mould T, Murdoch J, Oram D, Rabideau DJ, Reynolds K, Scott I, Seif MW, Sharma A, Singh N, Taylor J, Warburton F, Widschwendter M, Williamson K, Woolas R, Fallowfield L, McGuire AJ, Campbell S, Parmar M, Skates SJ (2016) Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 387 (10022):945-956. https://doi.org/10.1016/S0140-6736(15)01224-6
doi: 10.1016/S0140-6736(15)01224-6
pubmed: 26707054
pmcid: 4779792
Goff BA, Mandel LS, Drescher CW, Urban N, Gough S, Schurman KM, Patras J, Mahony BS, Andersen MR (2007) Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 109 (2):221-227. https://doi.org/10.1002/cncr.22371
doi: 10.1002/cncr.22371
Chung SH, Lee SY, Ju W, Kim SC (2013) Clinical efficacy of serum human epididymis protein 4 as a diagnostic biomarker of ovarian cancer: A pilot study. Obstet Gynecol Sci 56 (4):234-241. https://doi.org/10.5468/ogs.2013.56.4.234
doi: 10.5468/ogs.2013.56.4.234
pubmed: 24328008
pmcid: 3784136
Yabuuchi H, Matsuo Y, Sunami S, Kamitani T, Kawanami S, Setoguchi T, Sakai S, Hatakenaka M, Kubo M, Tokunaga E, Yamamoto H, Honda H (2011) Detection of non-palpable breast cancer in asymptomatic women by using unenhanced diffusion-weighted and T2-weighted MR imaging: comparison with mammography and dynamic contrast-enhanced MR imaging. Eur Radiol 21 (1):11-17. https://doi.org/10.1007/s00330-010-1890-8
doi: 10.1007/s00330-010-1890-8
pubmed: 20640898
Passaperuma K, Warner E, Causer PA, Hill KA, Messner S, Wong JW, Jong RA, Wright FC, Yaffe MJ, Ramsay EA, Balasingham S, Verity L, Eisen A, Curpen B, Shumak R, Plewes DB, Narod SA (2012) Long-term results of screening with magnetic resonance imaging in women with BRCA mutations. Br J Cancer 107 (1):24-30. https://doi.org/10.1038/bjc.2012.204
doi: 10.1038/bjc.2012.204
pubmed: 22588560
pmcid: 3389408
Warner E, Hill K, Causer P, Plewes D, Jong R, Yaffe M, Foulkes WD, Ghadirian P, Lynch H, Couch F, Wong J, Wright F, Sun P, Narod SA (2011) Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol 29 (13):1664-1669. https://doi.org/10.1200/jco.2009.27.0835
doi: 10.1200/jco.2009.27.0835
pubmed: 21444874
pmcid: 4874196
Elezaby M, Lees B, Maturen KE, Barroilhet L, Wisinski KB, Schrager S, Wilke LG, Sadowski E (2019) BRCA Mutation Carriers: Breast and Ovarian Cancer Screening Guidelines and Imaging Considerations. Radiology 291 (3):554-569. https://doi.org/10.1148/radiol.2019181814
doi: 10.1148/radiol.2019181814
pubmed: 31038410
Andreotti RF, Timmerman D, Strachowski LM, Froyman W, Benacerraf BR, Bennett GL, Bourne T, Brown DL, Coleman BG, Frates MC, Goldstein SR, Hamper UM, Horrow MM, Hernanz-Schulman M, Reinhold C, Rose SL, Whitcomb BP, Wolfman WL, Glanc P (2020) O-RADS US Risk Stratification and Management System: A Consensus Guideline from the ACR Ovarian-Adnexal Reporting and Data System Committee. Radiology 294 (1):168-185. https://doi.org/10.1148/radiol.2019191150
doi: 10.1148/radiol.2019191150
pubmed: 31687921
Lee MV, Katabathina VS, Bowerson ML, Mityul MI, Shetty AS, Elsayes KM, Balachandran A, Bhosale PR, McCullough AE, Menias CO (2017) BRCA-associated Cancers: Role of Imaging in Screening, Diagnosis, and Management. Radiographics 37 (4):1005-1023. https://doi.org/10.1148/rg.2017160144
doi: 10.1148/rg.2017160144
pubmed: 28548905
Nandy S, Mostafa A, Hagemann IS, Powell MA, Amidi E, Robinson K, Mutch DG, Siegel C, Zhu Q (2018) Evaluation of Ovarian Cancer: Initial Application of Coregistered Photoacoustic Tomography and US. Radiology 289 (3):740-747. https://doi.org/10.1148/radiol.2018180666
doi: 10.1148/radiol.2018180666
pubmed: 30204078
pmcid: 6283286
Lengyel E (2010) Ovarian cancer development and metastasis. Am J Pathol 177 (3):1053-1064. https://doi.org/10.2353/ajpath.2010.100105
doi: 10.2353/ajpath.2010.100105
pubmed: 20651229
pmcid: 2928939
Nougaret S, Lakhman Y, Gonen M, Goldman DA, Micco M, D'Anastasi M, Johnson SA, Juluru K, Arnold AG, Sosa RE, Soslow RA, Vargas HA, Hricak H, Kauff ND, Sala E (2017) High-Grade Serous Ovarian Cancer: Associations between BRCA Mutation Status, CT Imaging Phenotypes, and Clinical Outcomes. Radiology 285 (2):472-481. https://doi.org/10.1148/radiol.2017161697
doi: 10.1148/radiol.2017161697
pubmed: 28628421
pmcid: 5673044